Relating to: cost-sharing cap on insulin.
Wisconsin bill limits patient out-of-pocket insulin costs to reduce financial barriers for diabetic residents requiring this life-sustaining medication.
Wisconsin bill limits patient out-of-pocket insulin costs to reduce financial barriers for diabetic residents requiring this life-sustaining medication.
AB 921 establishes a cost-sharing cap on insulin for Wisconsin residents with health insurance. The bill limits out-of-pocket expenses (copayments, coinsurance, and deductibles) that patients must pay for insulin to a specified amount per month or prescription. This follows similar legislation enacted in other states to address rising insulin costs.
Insulin is a life-sustaining medication for people with type 1 diabetes and many with type 2 diabetes, yet prices have tripled over the past two decades, forcing some patients to ration doses or skip payments. A cost-sharing cap directly reduces the financial burden on insulin-dependent Wisconsinites and improves medication adherence, which prevents serious health complications and reduces overall healthcare costs. This addresses a documented public health crisis affecting approximately 600,000+ Wisconsin residents with diabetes.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.